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Abstract
Colorectal cancer is one of the few malignant tumors in 
which synchronous or metachronous liver metastases 
[colorectal liver metastases (CRLMs)] may be treated 
with surgery. It has been demonstrated that resection 
of CRLMs improves the long-term prognosis. On the 
other hand, patients with un-resectable CRLMs may 
benefit from chemotherapy alone or in addition to liver-
directed therapies. The choice of the most appropriate 
therapeutic management of CRLMs depends mostly on 
the diagnostic imaging. Nowadays, multiple non-invasive 
imaging modalities are available and those have a pivotal 
role in the workup of patients with CRLMs. Although 
extensive research has been performed with regards 
to the diagnostic performance of ultrasonography, 
computed tomography, positron emission tomography 
and magnetic resonance for the detection of CRLMs, 
the optimal imaging strategies for staging and follow 
up are still to be established. This largely due to the 
progressive technological and pharmacological advances 
which are constantly improving the accuracy of each 
imaging modality. This review describes the non-invasive 
imaging approaches of CRLMs reporting the technical 
features, the clinical indications, the advantages and 
the potential limitations of each modality, as well as 
including some information on the development of new 
imaging modalities, the role of new contrast media and 
the feasibility of using parametric image analysis as 
diagnostic marker of presence of CRLMs. 
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Core tip: The present review describes the non invasive 
imaging approaches of colorectal liver metastases 
colorectal liver metastases (CRLMs) reporting the technical 
features, the clinical indications, the advantages and the 
potential limitations of each modality [ultrasonography, 
computed tomography (CT); magnetic resonance imaging 
(MRI), positron emission tomography (PET)/CT, PET/MRI] 
as well as including some information on the development 
of new imaging modalities, the role of new contrast media 
and the feasibility of using parametric image analysis as 
diagnostic marker of presence of CRLMs.
Mainenti PP, Romano F, Pizzuti L, Segreto S, Storto G, 
Mannelli L, Imbriaco M, Camera L, Maurea S. Non-invasive 
diagnostic imaging of colorectal liver metastases. World J Radiol 
2015; 7(7): 157-169  Available from: URL: http://www.wjgnet.
com/1949-8470/full/v7/i7/157.htm  DOI: http://dx.doi.org/10.4329/
wjr.v7.i7.157
INTRODUCTION
Annually over 130000 new cases of colorectal cancer 
(CRC) are diagnosed in the United States, representing 
the third most common cancer in both men and women, 
with more than 50000 deaths each year[1].  
Liver metastases are detected approximately in 
up to 20%-25% of patients with CRC at the time of 
diagnosis[2]. The 5-year cumulative rate of metachronous 
colorectal liver metastases [colorectal liver metastases 
(CRLMs)] is reported to be 15%[2]. Overall, approximately 
50% of patients with CRC will develop liver metastases[3]. 
CRC is one of the few malignant tumors in which 
synchronous or metachronous liver metastases may 
be treated with surgery. CRLMs are resectable in about 
20%-30% of the cases[4] with a 5-year survival of about 
50%-60% in comparison to a survival of less than 5% 
of patients with CRLMs not amenable to liver surgery[5]. 
In patients who are not suitable candidates for 
surgery, chemotherapy alone or in addition to local 
hepatic treatments, such as intrahepatic arterial infusion 
chemotherapy or radiofrequency ablation or laser therapy 
or cryotherapy, may be performed. These treatments 
options have been shown to increase survival, too[6-11].
Common to any therapy is the need for pretreatment 
anatomic planning to assess feasibility and avoid injury 
to adjacent structures such as vasculature, biliary ducts 
and surrounding organs. 
The surgical criteria, which permit to select the 
candidates for liver resection, are represented by the 
size of the lesion, number and location with respect to 
anatomic landmarks of the CRLMs, as well as the number 
of segments involved, the volume of the remaining liver 
and the general clinical parameters[6,7]. Metastases can be 
completely resected if at least 2 adjacent liver segments 
can be spared and if the future liver remnant is at least 
20% of total pre-resection liver volume[8] in patients with 
normal liver function and more than 40% in patients with 
reduced liver function[12,13]. 
Moreover anatomic variants of hepatic arteries, biliary 
tree and portal venous system need to be excluded 
because the surgical resection may be problematic, and 
thus additional surgery steps may be required[14]. 
Obviously, diagnostic imaging plays a crucial role 
in selecting the more appropriate therapy for patients 
with CRLMs, by detecting the lesions, determining the 
resectability and assessing the response to treatments. 
Even though many non invasive imaging modalities 
are now available and effective in detection and follow 
up of CRLMs, such as ultrasonography (US), computed 
tomography (CT), positron emission tomography (PET) 
and magnetic resonance imaging (MRI), each offering 
some advantages as disadvantages over the others, the 
optimal imaging strategy in patients with CRLMs have 
still to be designed. 
The lack of a worldwide well defined CRLMs imaging 
protocol is in part due to continuous and rapid tech-
nological and pharmacological developments which 
are progressively improving the performance of each 
imaging modality. 
This review describes the non-invasive imaging 
approaches of CRLMs reporting the technical features, 
the clinical indications, the advantages and the potential 
limitations of each modality, as well as including some 
information on the development of new imaging moda-
lities, the role of new contrast media and the feasibility of 
using parametric image analysis as diagnostic marker of 
presence of CRLMs. 
US
Because of its non-invasive character, low cost, no radia-
tion exposure, good patient acceptance and widespread 
availability, US is often the first choice for screening 
patients with malignancy and/or suspected liver lesions,
and it is widely used in the evaluation of liver meta-
stases[15-19]. 
In particular, the sensitivity of US for CRLMs detec-
tion is variable ranging from 50% to 76%[17,20]; however 
US sensitivity depends mostly on the size of the lesion 
and it can be as low as 20% if liver lesions are less than 
10 mm[15,16]. Despite of this limitation, in daily practice, 
US plays still a clinical role in distinguishing two different 
groups of patients with liver metastases: (1) patients 
with diffuse metastases who are no longer eligible for 
curative treatment; and (2) patients without metastases 
or a very limited number of them. Further diagnostic 
investigation with tomographic imaging is mandatory 
for the patients of the group 2 to define the correct 
therapeutic management. 
During the last few years, the contrast-enhanced 
ultrasound (CEUS) has progressively gained a huge role 
in the evaluation of liver lesions, improving detection 
and characterization of both primary or secondary 
liver lesions[21-28]. The added role of CEUS compared 
to the baseline US (b-US) has been observed for 
CRLMs detection, too[29]. A few studies have shown a 
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significantly better sensitivity of CEUS vs b-US in the 
identification of CRLMs measuring less than 10 mm; 
moreover CEUS should replace b-US for the detection 
of CRLMs in patients being treated with neoadjuvant 
systemic chemotherapy[30-33].
Westwood et al[29] in their recent meta-analysis 
of 19 studies on liver CEUS with Sonovue stated that 
CEUS shows a similar performance to liver CT and MRI 
in the characterization of incidentally detected focal liver 
lesions with lower costs respect to MRI and it may be 
adequate to rule out CRLMs; in particular, similarly to CT 
and MRI even with CEUS the CRLMs are better detected 
in post-contrast portal and late phases[31].
Nevertheless some limitations of CEUS need to 
be considered. CEUS presents still low sensitivity for 
very small focal liver lesions (< 5 mm), due to the low 
spatial resolution, and thus very small CRLMs might be 
missed[29]. In addition, CEUS does not go beyond certain 
limitations of the US examinations, like the difficulty 
in the evaluation of the sub-diaphragmatic liver or the 
interposition of the intestine, and above all the notable 
weakness of being operator dependent. Moreover liver 
steatosis and fibrosis are an important limitation that 
can increase the possibility of missing deep seated 
metastases[34]. Finally, another aspect to consider is 
that CEUS does not offer comprehensive information for 
surgical planning as both CT and MRI do. Bolondi et al[35] 
report that even if the use of CEUS is largely accepted 
in clinical practice its role in the diagnostic algorithm of 
liver lesions has not yet been established. 
Beyond the scope of the present review because of 
the invasive approach, the following US technique merit 
to be mentioned: the US-guided percutaneous biopsy 
which allow characterizing indeterminate hepatic lesions 
and the intra-operative ultra-sonography which offer the 
highest accuracy rates in CRLMs detection[36,37]. 
MULTIDETECTOR CT 
Multidetector CT MDCT is considered the imaging 
modality of choice for CRC staging and follow up, 
because it provides excellent coverage of the entire 
chest/abdomen/pelvis offering a global one session 
staging. Nevertheless up to 25% of CRLMs may be 
missed[38]. The current MDCT devices enable high spatial 
resolution studies of the entire liver generating slice 
thickness ≤ 1 mm and isotropic pixel sizes and, thus, 
allowing high quality reformatted multiplanar (MPR) 
and volumetric three-dimensional rendering (3D VR) 
reconstructions. The resulting high definition images 
define accurately the main features of each lesion, as the 
sizes, the margins, the segmental spatial distribution, 
the relation with the vascular and biliary structure, and 
the volume of the remaining liver. 
The additional diagnostic value of using thin colli-
mation in the detection of hepatic lesions is debated. 
Some authors have demonstrated that the use of a 
thinner section thickness (i.e., 2.5 mm vs ≥ 5 mm 
slice thickness) at CT improves the detection of hepatic 
lesions[39], as well as, the accuracy of 16-MDCT using 
a 1.5 mm collimation might be superior to previous CT 
techniques in differentiating between hepatic metastases 
and hepatic cysts[40]. On the contrary, other authors 
reported that image reconstruction with MDCT at 
collimations less than 5 mm did not improve sensitivity in 
the detection of hepatic metastases 1.5 cm or smaller[41], 
as well as, a slice thickness ≤ 1 mm does not improve 
hepatic lesion detection and it provides a significant 
increase of image noise[42]. As a result of the above 
information, a CRLMs protocol scanning of 2-4 mm of 
collimation may be recommended. 
The value of unenhanced scans lies mainly in the 
characterization of small lesions as being solid or cystic 
or in the identification of calcified CRLMs. About the 
contrast-enhanced (ce) scanning protocol, the venous 
phase is well recognized as the optimal timing to 
detect CRLMs. Arterial and equilibrium phase CT have 
no incremental value compared to hepatic venous 
phase MDCT in the detection of CRLMs, as a result a 
multiphasic scanning protocol implies an unjustified 
additional radiation exposure[43,44]. Moreover the single 
portal venous phase contrast enhanced MDCT (ce-
MDCT) scanning protocol enables accurate preoperative 
assessment of the local CRC staging (T and N), too[45]. 
The performance of MDCT in the CRLMs detection is 
variable showing unsatisfactory sensitivity and specificity 
values for lesions < 10 mm[46] or in presence of fatty 
liver which is often a consequence of chemotherapy[47]. 
Furthermore, incidental findings such as small heman-
giomas and cysts measuring less than 10 mm in size can 
be difficult to differentiate from metastases because of 
volume averaging[48,49]. 
Contrast medium allergies as well as renal impair-
ment may limit the use of the ce-CT; however they do 
not represent absolute contraindications because of the 
possibility of a supporting therapy. 
MRI
Currently, MRI represents the most accurate modality 
for evaluating CRLMs; it provides anatomic details and 
has a high detection rate, even for lesions smaller than 
10 mm[38,48-51]. 
The recent technological advances (high magnetic 
field strength > 1 T, high gradients, parallel imaging 
techniques, fast dynamic sequences, breath-hold 
sequences) have improved the liver application of MRI 
increasing the signal-to-noise ratio, the contrast-to-
noise ratio (CNR), the spatial resolution and the image 
quality as well as reducing the scan times.
The unenhanced standard MRI protocol for detecting 
and characterizing focal liver lesions includes both T1- 
and T2-weighted images. For T1-weighted imaging, the 
in-phase and opposed-phase gradient-recalled echo 
(GRE) sequences are acquired to assess the presence of 
parenchymal fatty infiltration or focal sparing of diffuse 
fatty infiltration. For T2-weighted imaging, the turbo-
spin echo (TSE) or the fast spin echo without and with 
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have to be reported about the differences between 
MRI and CT contrast-enhanced scanning protocol: the 
exposure to ionizing radiation suggests to use single 
phase CT protocol and to reserve multiphasic studies 
only when really necessary; although the MRI of the 
liver is the most accurate modality for detecting CRLMs, 
in the clinical practice it is frequently used after a staging 
whole-body ce-MDCT to solve problems of differential 
diagnosis; that is why a multiphasic MRI liver protocol 
may be necessary to characterize correctly a liver lesion 
defined as undetermined at ce-MDCT. 
Gadolinium-based contrast agents may cause 
collateral effects, such as acute non-renal adverse 
reactions (e.g., anaphylactoid reactions), acute renal 
adverse reactions (e.g., contrast induced nephropathy), 
delayed adverse reactions [nephrogenic systemic fibrosis 
(NSF)] and problems at the site of injection (e.g., local 
necrosis)[60]. NSF is a rare potentially fatal disease 
that has been observed in patients with severe renal 
insufficiency exposed to gadolinium contrast agent. 
To prevent the risk of NSF it is suggested to avoid the 
intravenous (iv) administration of gadolinium contrast 
agents in patients who have a glomerular filtration rate 
lower than 30 mL/min per 1.73 m2 as well as in those 
who are on dialysis or have acutely renal impairment. 
This point represents a recommendation rather than an 
absolute contraindication.  
Reticulo-endothelial contrast agents
All reticuloendothelial system (RES) agents are super-
paramagnetic iron oxide-based contrast agents (SPIO). 
SPIO particles are taken up by RES cells of the normal 
liver parenchyma, the spleen and the lymph nodes. They 
shorten T2 and T2* relaxation times resulting in a loss 
of signal intensity in normal liver parenchyma. On the 
opposite, malignant liver lesions do not have a substantial 
number of RES cells and appear as hyperintense lesions 
with distinct borders in contrast to the hypointense liver 
parenchyma after application of SPIO on T2-weighted 
MRI. 
Although SPIO agents have showed high accuracy in 
the detection of liver lesions[40,61-64], hepatocyte-specific 
contrast agents are preferred to these molecules in 
clinical practice[65].
Hepato-biliary contrast agents
Hepatobiliary agents represent a heterogeneous group 
of paramagnetic molecules of which a fraction is taken 
up by hepatocytes and excreted into the bile. On T1 
weighted images, lesions not containing hepatocytes are 
hypointense to the surrounding enhanced parenchyma 
during the hepato-biliary phase (HBP). Presently, the 
hepatobiliary agents actually available are mangafodipir 
trisodium (MT, Teslascan®, GE Healthcare), godobenate 
dimeglumine (Gd-BOPTA, Multihance®, Bracco) and 
gadoxetic acid (Gd-EOB-DTPA, Primovist®, Schering). 
MT has limited assessment of vascular structures due 
to its inability to be administered as a bolus. Gd-BOPTA 
and Gd-EOB-DTPA show biphasic liver enhancement 
fat suppression are preferred over the single-shot TSE 
pulse sequences, because the latter do not offer an 
optimal soft tissue contrast. For detection of focal lesions 
a TE of approximately 80-100 ms is adopted, however 
a heavily T2-weighted sequences with a time of echo of 
approximately 160-180 ms may help in differentiation 
between solid and non-solid lesions (e.g., metastasis/
HCC vs haemangioma/cyst)[52-54].
Recent clinically important advances in MRI include 
the addition of diffusion-weighted imaging (DWI). DWI is 
a functional technique that looks at the Brownian motion 
of water in tissues. In biological tissues, the Brownian 
motion is restricted by interactions with cell membranes 
and macromolecules on a microscopic level as well as 
it is modified by any architectural tissue changes[55]. 
Increased tissue cellularity observed in tumors restricts 
Brownian motion, which can be quantified by calculation 
of the apparent diffusion coefficient (ADC) on derived 
ADC parametric maps. Of note, ADC has been shown 
to be inversely correlated with tumor cellularity and it 
can be considered a quantitative biomarker parameter 
of pathology. Metastases tend to restrict diffusion and 
the addition of DWI to the standard liver MRI protocol 
improves sensitivity and specificity for lesion detection 
and characterization[56-58]. The added value of DWI is 
even more evident in the detection of CRLMs ≤ 1 cm 
with sensitivity of 92% compared to 71% of late phase 
hepato-biliary contrast agent MRI[59]. Hence, these 
sequences are now routinely included in a liver MRI 
protocols. 
Successively, the contrast-enhanced sequences 
are performed. Three different groups of MRI contrast 
agents for hepatic imaging are available: the non-specific 
extracellular gadolinium chelates, the organs-specific 
(reticulo-endothelial) and the liver-specific intracellular 
(hepato-biliary) contrast agents. 
Non-specific gadolinium chelates
Extracellular gadolinium chelates are the contrast agent 
more frequently used for MRI. Several agents with similar 
properties are on the market, including gadopentetate 
dimeglumine (Magnevist, Schering, Berlin, Germany), 
Gd-DTPA-BMA (Omniscan®, GE Healthcare, Chalfont 
St. Giles, United Kingdom) and Gd-DOTA (Dotarem, 
Guerbet, Aulnay-sous-Bois, France). 
Non-specific extracellular gadolinium chelates have 
pharmacokinetics similar to those of iodinated contrast 
agents and are excreted almost exclusively by passive 
glomerular filtration through the kidneys. Because of 
their small size, gadolinium chelates are rapidly cleared 
from the intravascular space into the extracellular 
interstitial space according to the concentration difference 
of the contrast agent between the two compartments. 
The transfer of the molecules occurs in the opposite 
direction, when the concentration gradient inverts[60]. 
About the contrast-enhanced scanning protocol, 
the T1-weighted 3D-GRE breath hold (BH) sequences 
are obtained during the arterial, portal venous phase 
and the equilibrium phase. The following considerations 
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with an early vascular and extracellular phase allowing 
arterial, portal venous and equilibrium phase and a 
delayed HBP with a peak to 20-40 min for Gd-EOB-
DTPA and 60-90 min for Gd-BOPTA. The advantages 
of the Gd-EOB-DTPA over Gd-BOPTA are the higher 
biliary excretion approximately close to the 50% of the 
delivered dose respect to 3%-5%, the high relaxivity, 
the earlier onset and the longer duration of contrast, 
which facilitates imaging and image quality[65,66].
HBP improves the sensitivity of MRI in the detection of 
CRLMs[59]. In addition hepatocyte-specific contrast agents 
allow detection of the “disappearing liver metastases”[13],
which mimic a complete response to neoadjuvant che-
motherapy leading to a mismatch between imaging 
response and true pathological complete response. A 
false complete imaging response is more often observed 
with CT and PET-CT[67], while the current data suggest 
that MRI with hepato-biliary contrast agents represent 
the most appropriate imaging modality for assessment 
of patients with CRLMs treated with neoadjuvant 
chemotherapy[68].
Despite of the great ability of MRI in detection of 
CRLMs, above all with the introduction of DWI and 
HBP, this modality still presents some limitations in 
patients who have difficulty holding their breath. 
Motion artefacts can heavily degrade images especially 
in dynamic acquisitions. Different sequences can be 
performed to study dynamic and HBP such as volumetric 
interpolated BH examination (Siemens Healthcare, 
Erlangen, Germany), liver acquisition with acceleration 
volume acquisition (GE Healthcare, Waukesha, Wis), or 
enhanced high-resolution isotropic volume excitation 
(Philips Healthcare, Best, the Netherlands) or respiratory-
triggered T1-WI, this latter independent from patient’s
collaboration[69]. Recently Yoon et al[70] have evaluated 
in a large number of patients the image quality and 
diagnostic performance in evaluation of focal liver lesions 
of the respiratory-triggered 3D T1W-GRE sequence 
compared to standard BH T1W-GRE in HBP. Their results 
demonstrate that in no-collaborative patients respiratory-
triggered 3D T1W-GRE images showed clearer liver 
margins and intrahepatic vascular structures as well as 
better image quality, so providing a better diagnostic 
performance. Overall image quality of respiratory-
triggered 3D T1W-GRE was also better than that of 
BH T1W-GRE in patients with sufficient breath-holding 
capacity (n = 309, 3.96 ± 0.88, 3.81 ± 0.6, respectively, 
P < 0.001).
18F-FDG-PET AND 18F-FDG-PET/CT
18F-FDG-PET is the most sensitive non-invasive imaging 
modality for the detection of CRLMs on a per patient 
basis[15,38,49,50]; however PET is limited by the low spatial 
resolution, the lack of clear anatomic landmarks, and 
the physiological uptake of the parenchyma which can 
mask small hepatic lesions. As a result, the detection 
of CRLMs by 18F-FDG-PET is directly related to the size 
of the liver metastases: 14% of hepatic lesions ≤ 15 
mm[71] and 5%-36% of hepatic lesion ≤ 10 mm[72-74] 
were identified by 18F-FDG-PET. 
Therefore, to overcome the above limitations, PET 
has been combined with CT to realize the hybrid modality 
PET/CT. This combination provides simultaneous 
functional and anatomic diagnostic information. The 
combination of PET with CT improves the distinction of 
physiological 18F-FDG uptake from pathology and also 
aids the localization of metastases within the segmental 
anatomy of the liver, but does not overcome the intrinsic
limits of PET modality such as the poor spatial resolution 
or the inaccurate identification of small non-hyper-
metabolic lesions. That is why performing the CT of 
the PET/CT examination with the administration of iv 
iodinated contrast medium improves the performance 
of the PET/CT modality. 18F-FDG-PET/ce-CT increases 
significantly the detection of CRLMs compared with 
18FDG-PET/CT[75]. 
18F-FDG-PET does not require breath holding during 
acquisition, thus respiratory movements may reduce 
conspicuity of small liver lesions with potential errors 
in the detection of focal sub-diaphragmatic 18F-FDG 
uptakes and respiratory phase mismatch between 
the PET and CT data. Revheim et al[76] have recently 
investigated the added role of two tailored 18F-FDG-
PET liver protocols [prolonged liver acquisition time (PL-
PET) and repeated breath-hold respiratory gated liver 
acquisition (RGL-PET)] to a standard whole body (sWB) 
18F-FDG-PET/CT protocol to improve detection of CRLMs. 
The PL-PET protocol lasted 8 min and covered the liver 
with two bed positions, while patients of the RGL-PET 
protocol were asked to alternate breaths and BHs for 10 
min. The addition of tailored liver-specific 18F-FDG PET 
protocols to sWB-PET scan improved the detection of 
CRLMs compared to sWB-PET alone; more lesions were 
detected and a higher CRLMs SUV max was measured, 
with a substantial reduction of the background noise 
related to physiologic liver uptake. 
The role of PET/CT in CRLMs is yet evolving. Due 
to the high cost and an additional radiation exposure, 
18F-FDG-PET/CT is reserved for the detection of occult 
extra-hepatic disease in patients with CRLMs amenable 
of surgical resection to avoid the morbidity of a futile 
invasive therapy[77].
Moreover further clinical roles of 18F-FDG-PET/CT 
may be the following: (1) identification of the primary 
colorectal neoplasm and evaluation of its local extent[78,79]; 
(2) after a curative resection, the detection of local or 
distant recurrence of the disease[80] as well as solving 
ambiguous cases of unexplained CEA rise without 
conventional radiological explanation and in their pro-
gnostic stratification[81]; and (3) metabolic monitoring of 
the tumor response to the therapy[82]. 
18F-FDG-PET/MRI
As stated above, both PET and CT show a few limitations 
in the evaluation of liver lesions; recently PET/MRI has 
been proposed as an alternative hybrid imaging modality. 
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Because of the great sensitivity of MRI in recognizing 
small liver metastases, its combination with the 
metabolic data obtained by PET may lead to an improved 
diagnostic accuracy. 
Nowadays, the role of PET-MRI in evaluating CRLMs 
is becoming a topic of major interest, however at 
present insufficient data is available because hybrid 
devices are present in few highly specialized centers. 
Recent studies have enrolled patients with CRLMs 
to evaluate the performance of PET-MRI[83-85]. Drzezga 
et al[85] compared PET/CT and PET-MRI in 32 oncologic 
patients, four of those had CRC and with seven liver 
lesions. Overall conclusion of this study was that PET/
MRI was comparable to PET/CT. Quick et al[86] studied 80 
patients who underwent a double-scanning protocol with 
PET/ MRI and PET/CT with 195 tracer-avid lesions and 
rated image quality. Their results show that integrated 
PET/MR hybrid imaging is feasible in clinical setting with 
similar detection rates as those of PET/CT. Partovi et al[87] 
and Kershah et al[88] investigated the role of PET/MRI in 
120 patients with various primary neoplasms (13 CRCs) 
who underwent double-scanning protocol with PET/MR 
and PET/CT in a sequential design following a single-
tracer injection of FDG. They observed that hybrid PET-
MRI imaging led to a better diagnostic confidence in the 
characterization of focal liver lesions, taking advantage 
from the synergic evaluation of ADC and SUVmax. 
Nielsen et al[89] investigated the possible role of PET/MRI 
in evaluation of therapeutic response in twenty patients 
with CRLMs treated with radiofrequency or microwave 
ablation. The sensitivity of MRI in detecting small 
intrahepatic lesions combined with the ability of 18F-FDG-
PET to visualize enhanced metabolism at the ablation 
site suggests that 18F-FDG-PET/MRI could potentially 
improve the accuracy of early detection of progressive 
disease, and thus allow swifter and more effective 
decision-making regarding appropriate treatment. 
NON-CONVENTIONAL PARAMETRIC 
IMAGING OF CRLMs
This section is dedicated to morphological and functional 
liver parametric imaging proposed for detecting occult 
CRLMs and predicting which patients are at risk to 
develop metachronous liver disease. At present, the real 
role of parametric images has to be further investigated, 
as a result they are not routinely performed in the 
diagnostic clinical management of patients with CRC.  
Different studies[90,91] have focused on methods 
targeting liver perfusion to individuate occult CRLMs 
before they become overt on morphological imaging. 
Changes of liver hemodynamics may indeed be related 
to the presence of occult liver metastases and may also 
predict the development of metachronous ones. It is well 
known that the liver receives a dual blood supply from 
the portal and systemic circulation. Normally in healthy 
subjects approximately two thirds of this blood supply is 
carried by the portal vein and one third by the common 
hepatic artery. During the onset of liver metastases this 
relation changes because of the increase of arterial blood 
flow (arterialization) and decrease of portal venous in-
flow[92]. 
Imaging can allow recognizing and quantifying 
these perfusional changes occurring in the liver micro-
vasculature even before any visible morphological signs. 
For this purpose, doppler perfusion index (DPI) is an 
US measure of the ratio of arterial hepatic blood flow to 
total hepatic blood flow[93,94]. Kopljar et al[95] compared 
two different groups with and without liver metastases 
and observed that patients with liver metastases 
showed greater DPI determined by increased arterial 
hepatic blood flow associated to a smaller portal cross-
sectional area portal blood flow. The strong operator 
dependence of the technique represents the major limit 
of this method. 
Perfusion CT allows evaluation hepatic hemodynamic 
changes and provides quantitative perfusional data 
useful for the precocious detection of liver metastases[96]. 
However, to produce reliable enhancement curves the 
perfusion CT necessitates of multiple high temporal 
resolution acquisitions after administration of iv contrast 
medium, this leads to radiation overexposure; moreover 
the breathing cycle can cause severe motion and dis-
tortion artifacts[97]. 
Thanks to the lack of ionizing exposure, perfusion 
MRI seems to be more promising as a reliable tool for the 
evaluation of focal and global perfusion indexes[98]. The 
perfusion parameters evaluated with dynamic contrast-
enhanced MRI are essentially represented by Ktrans 
(volume transfer constant) and Kep (rate constant). 
Ktrans is the rate constant of contrast agent transfer 
from the plasma compartment into the extracellular 
extravascular space, whereas Kep is the rate constant 
of contrast agent that escape from the extracellular 
extravascular space back into the plasma compartment. 
De Bruyne et al[99] found that a decrease in Ktrans 
of more than 40% after bevacizumab-containing 
chemotherapy was associated with better progression-
free survival. Further investigations are needed to 
understand the real role of perfusion MRI in CRLMs. 
Different authors[100-103] have investigated the role of 
CT texture analysis (TA) to identify the early changes in 
liver texture heralding the possible presence of occult 
liver micro-metastases. Texture analysis does not require 
any additional phase and it can be easily obtained from 
routinely acquired clinical CT data. This technique is 
based on the assumption that presence of liver occult 
lesions can be suspected by the amount of spatial 
heterogeneity on CT which can be assessed quantifying 
the texture parameters. These parameters go beyond 
human visual evaluation and include as main explored 
values the brightness (quantitative measurement of the 
mean grey level intensity), entropy (grade of inhomo-
geneity) and uniformity (distribution of grey levels). 
As different studies are investigating the potential role 
of TA, it is debated which is the more appropriate CT 
phase to analyze. Ganeshan et al[100] applied TA to non-
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contrast enhanced CT scan of patients with CRC showing 
significant changes of TA parameters in the non diseased 
part of the liver of patients with CRLMs compared to 
those without. Similar results are reached even using 
TA on routinely acquired portal phase images[101-103]. 
The exact reasons to explain the relationship between 
an altered texture in apparently disease-free liver areas 
and the presence of occult micro-metastases or the 
development of metachronous live metastases are not 
quite clear. Probably the alterations of texture features 
are related to subtle tumor-induced structural and/or 
hemodynamic changes. 
As it has been well demonstrated that the presence 
of micro-metastasis is related to subtle changes in 
liver hemodynamics, some authors are investigating 
the role of blood oxygenation level dependent MRI in 
early detection of CRLMs. Barash et al[104,105] evaluated 
in mice the pathological changes in liver perfusion 
assessing the hemodynamic response imaging (HRI), a 
method that involves hypercapnic challenge with brief 
inhalation of 5% CO2 followed by hyperoxic challenge 
with brief inhalation of carbogen. They demonstrated 
that during CO2 enrichment there is an increase in 
portal flow compared to arterial hepatic flow, and that 
the higher deoxyhemoglobin levels produced a decrease 
in fMRI signal intensity. Conversely hyperoxia signifies 
vascular density and tissue perfusion. Edrei et al[106,107] 
more recently applied this method to demonstrate in 
a mouse model the early hemodynamic changes that 
occur in CRLMs, and their modification with advance of 
liver involvement. The HRI method showed enhanced 
sensitivity for small CRLM (1-2 mm) detection compared 
with ce-MRI (82% vs 38%, respectively) as well as it 
demonstrated hemodynamic changes occurring during 
CRLMs antiangiogenic treatment. 
DETECTION OF CRLMs: WHICH IS THE 
MOST ACCURATE MODALITY?
A huge literature is available about the performances of 
each imaging modality in the evaluation of CRLMs; as a 
consequence, we will describe mostly the data of meta-
analysis reports in this section. 
Kinkel et al[15] performed a meta-analysis including 
papers published between 1985 and 2000 and concluded 
that, at equivalent specificity (≥ 85%), 18F-FDG-PET 
(90%; CI: 80, 97) is the most sensitive non invasive 
imaging modality compared to US (55%; CI: 41, 68), 
CT (72%; CI: 63, 80) and MR (76%; CI: 57, 91) for the 
detection of hepatic metastases from colorectal, gastric 
and esophageal cancers on a patient basis. 
Bipat et al[49] performed a meta-analysis including 
papers published between 1990 and 2003 and concluded 
that 18F-FDG-PET is the most sensitive diagnostic tool 
for the detection of hepatic metastases from CRC on 
a per patient basis, but not on a per lesion basis. On a 
per patient basis, the sensitivity of CT, MR, 18F-FDG-PET 
were 64% (CI: 55, 72), 65% (CI: 58, 70) and 76% (CI: 
61, 86), respectively. For lesion of 1 cm or larger SPIO-
enhanced MRI was the most accurate modality. 
Niekel et al[38] performed a meta-analysis including 
papers published between 1990 and 2010 and con-
cluded that, MRI is the preferred fist-line modality for 
evaluating CRLMs in patients who have not previously 
undergone therapy; it provides anatomic details and 
has a high detection rate for lesions smaller than 10 
mm. 18F-FDG-PET can be used as the second line-
modality because it is valuable in the evaluation of extra-
hepatic disease. The role of 18F-FDG-PET/CT was not 
clear owing the small number of studies. At equivalent 
specificity, the sensitivity of CT, MR and 18F-FDG-PET 
was 75% (CI: 69, 79), 80% (CI: 75, 62) and 81% (CI: 
66, 91), respectively, on a per lesion basis, and 84% 
(CI: 67, 93), 88% (CI: 65, 97) and 94% (CI: 92, 96), 
respectively, on a per patient basis. 
van Kessel et al[68] performed a meta-analysis 
including papers published between 2005 and 2011 and 
concluded that, MRI is the most appropriate imaging 
modality for preoperative assessment of patients with 
CRLMs treated with neoadjuvant chemotherapy. The 
sensitivity of CT, MRI, 18F-FDG-PET and 18F-FDG-PET/CT 
were 70% (CI: 47, 62), 86% (CI: 70, 94), 54% (CI: 
47, 62) and 52% (CI: 38, 65), respectively, on a per 
patient basis.  
Seo et al[108] reported the comparison of Gd-EOB-
DTPA-MRI and 18F-FDG-PET/ce-CT in 68 patients with 
103 CRLMs and concluded that Gd-EOB-DTPA-MRI is 
more accurate than 18F-FDG-PET/ce-CT, especially for 
detection of small (≤ 1 cm) lesions. The sensitivity, the 
specificity, the positive and negative predictive values 
on a patients basis were 100%, 71%, 97% and 100% 
respectively for Gd-EOB-DTPA-MRI, and 93%, 71%, 
97% and 57% respectively for 18F-FDG-PET/ce-CT. 
Muhi et al[109] reported the comparison of ce-
CT, ce-US, SPIO-MRI and Gd-EOB-DTPA-MRI in 111 
patients with CRC, 46 of whom presented 112 hepatic 
metastases. The sensitivity of ce-US, ce-CT, SPIO-
MRI and Gd-EOB-DTPA-MRI, was 73%, 63%, 80% 
and 95%, respectively, considering all the lesions, and 
41%, 26%, 63% and 92%, respectively, considering 
the lesions ≤ 10 mm. The sensitivity of MRI was 
significantly better than the other modalities. Although 
the sensitivity of Gd-EOB-DTPA-MRI was superior to 
that of SPIO-MRI especially for lesions ≤ 10 mm, the 
difference was not statistically significant. No significant 
differences in positive predictive value were disclosed 
between any of the images sets for all the lesions, 
lesions > 1 cm and lesions ≤ 1 cm. 
Berger-Kulemann et al[47] evaluated the performance 
of ce-MDCT and gadoxetic acid enhanced MRI in 
the detection of CRLMs in patients with diffuse fatty 
infiltration of the liver. MDCT identified 49 (72%) and MRI 
66 (97%) of 68 lesions confirmed by hystopathology. 
Statistical analysis showed that the MRI was superior 
to MDCT with a significant difference considering all the 
lesions (P < 0.001) and small lesions (≤ 1 cm; P < 
0.001), while there was no-significant difference between 
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the two modalities in the detection of lesions > 1 cm.
Zech et al[110] reported that Gd-EOB-DTPA-MRI can 
lead to cost savings respect to extracellular-contrast-
medium-MRI by improving pre-operative planning, reduc-
ing additional imaging and decreasing intra-operative 
changes. 
Chen et al[111] performed a meta-analysis including 
13 papers published between 2011 and 2012 (6/13 
papers dealt with CRLMs) and concluded that, Gd-
EOB-DTPA-MRI presents high sensitivity (93%; CI: 90, 
95) and specificity (95%; CI: 91, 97) for detection of 
CRLMs. 
Maffione et al[112] have evaluated the diagnostic 
performance of 18F-FDG PET and PET/CT for staging 
liver metastases in patients with CRC including in their 
meta-analysis studies published from 2004 to 2014. 
They conclude that 18F-FDG-PET/CT is highly accurate 
for the detection of CRLMs on a per-patient basis 
(pooled sensitivity and specificity of 93%) while on a 
per-lesion basis results were lower (pooled sensitivity 
and specificity of 60% and 79%). Comparing PET with 
different imaging modalities their results show that 
PET had a lower sensitivity than MRI and CT on a per-
patient basis (93%, 100% and 98%) and a per-lesion 
basis (66%, 89% and 79%). In contrast, PET appeared 
more specific than MRI and CT (86%, 81% and 67%).
Maas et al[80] published a meta-analysis comparing 
PET, PET-CT and CT for whole body staging in patients 
with suspected recurrence of CRC. The Authors found 
PET and PET-CT to have the highest diagnostic per-
formance with an area under the curve of 0.94 for both 
PET and PET-CT compared to 0.83 for CT scan. PET/CT 
appears as the whole body technique of choice because 
of its greater ability respect to CT to identify extra-hepatic 
and additional sites of disease and also for the detection 
of local recurrence. 
MANAGEMENT OF CRLMS: WHICH 
IMAGING PROTOCOL?
The main clinical scenarios to be managed in patients 
with CRLMs are the following: (1) detection of liver 
metastases as part of global staging of newly diagnosed 
CRC; and (2) pre-surgical planning of CRLMs resection; 
c) surveillance/monitoring of treatment response of the 
CRLMs. 
Although the optimal imaging strategy is not well 
established, yet, we will suggest a diagnostic algorithm 
for each clinical scenario underscoring in part information 
just reported above. 
 
Detection of CRLMs of newly diagnosed CRC 
ce-CT is currently regarded as the standard for one 
session whole-body staging, including the liver, for 
initially diagnosed CRC patients. However, as stated 
above, ce-CT may miss up to 25% of CRLMs also using 
a multiphasic acquisition protocol and its performance 
worsens in presence of hepatic steatosis[47]. Furthermore, 
ce-CT shows limitations in characterizing small (< 1 
cm) hypoattenuating lesions, which may be defined as 
indeterminate or “too-small-to-characterize” (TSCT)[46]. 
Currently, liver MRI is increasingly used to evaluate 
CRLMs. The higher accuracy of MRI in comparison with 
CT and PET/CT for detection of CRLMs, especially for 
lesions < 1 cm, has been just largely mentioned in 
the previous section. However, it is unclear which CRC 
patients should receive liver MRI in addition to standard 
staging CT. Recently, Han et al[113] have investigated 
the clinical impact of liver MRI in staging evaluation of 
newly diagnosed CRC patients in three ce-CT groups 
of patients: (1) patients who demonstrate diminutive 
indeterminate hypoattenuating TSCT lesions; (2) 
patients with metastasis-negative hepatic findings; and 
(3) suspicious or non-TSCT indeterminate lesions. The 
Authors concluded that liver MRI provides little benefit 
for detecting synchronous CRLMs in the groups 1 and 2, 
while it has a significant impact in the group 3. Moreover 
in the setting of hepatic steatosis, MRI with hepato-biliary 
contrast agents is superior to ce-MDCT in detecting 
CRLMs[47]. 
Both US and PET/CT play a marginal role. As stated 
above, US may be used to identify patients with diffuse 
liver metastases who may not need further hepatic 
diagnostic investigation, whereas PET/CT show a high 
performance in identifying patients with liver metastases. 
Pre-surgical planning of CRLMs resection
The current National Comprehensive Cancer Network 
(NCCN) guidelines state that liver MRI can be consider 
to further evaluate patients diagnosed with potentially 
resectable CRLMs on CT[114]. This recommendation takes 
into account the fact that liver MRI is most reliable in 
defining the number, the size and the location of CRLMs, 
may detect additional CRLMs that are undiagnosed 
on CT and therefore may change the treatment plan. 
Moreover it provides information about the volume of 
the future liver remnant, of the biliary ductal system 
and of the hepatic parenchyma, such as steatosis, iron 
deposition, fibrosis, that may impair liver function. 
ce-MDCT and ce-MRI angiography have shown similar 
performance for preoperative hepatic vascular anatomic 
evaluation[115], however CT may have some advantages 
over MRI as rapid acquisition, less susceptibility to 
motion, thin collimation, which assure excellent MPR 
and 3D images. ce-MDCT may be preferred to ce-MRI 
angiography in situations where detailed vascular infor-
mation is necessary prior to complex hepatic resection. 
18F-FDG-PET/CT may be recommended for the 
detection of occult extra-hepatic disease prior of CRLMs 
surgical resection to avoid not useful invasive treatment. 
Surveillance/monitoring of the treatment response of 
the CRLMs
As diagnostic imaging can help identify the best 
therapeutic strategy for treatment of CRLMs, equally it 
plays a key role in assessing response to treatment.
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The criteria for monitoring CRLMs response to 
chemotherapy are the response evaluation criteria in 
solid tumors, which consist of a simple single dimension 
measurement of tumor size with efficacy determined 
by tumor shrinkage[116]. In the evaluation of patients 
with CRLMs treated with chemotherapy, ce-MRI should 
be preferred to both ce-MDCT and 18F-FDG-PET/CT 
for the following reasons: (1) the steatosis induced by 
chemotherapy decreases the liver-to-lesion contrast, 
hindering the detection and delineation of the lesions 
on ce-MDCT; and (2) the necrosis, the reduction of the 
size of the lesions and the decrease in metabolic activity 
of cancer cells hamper the diagnostic performance of 
18F-FDGPET/CT; it is still not clear if the disappearance 
of metabolic activity of a lesion can be considered a 
complete response[117,118]. Today, MRI with DWI and liver 
specific contrast agents provide the most sensitive tool 
for detecting CRLMs in patients who have undergone 
neoadjuvant chemotherapy. 
After systemic or local therapy, the change in size 
of the CRLMs may not be representative of a response, 
because the initial post-treatment examinations often 
fail to demonstrate shrinkage of the tumor. In such 
cases radiologists can misinterpret a slight increase in 
size of a recently treated lesion as tumor progression, 
whereas it is often sign of early response to anti-
angiogenic treatment. The CT “pseudo-progression” is 
defined as the increase in size of a lesion after treatment 
associated with a reduction of attenuation, due to intra-
lesional edema, together with a decrease in the tumor 
markers[119]. In these instances, the evaluation of 
changes in size and enhancement of the lesion as well 
as following the lesion up over time, preferably using 
the same modality, helps determine the efficacy of the 
treatment[120]. 
After a local hepatic treatment, the current NCCN 
guidelines[114] suggest surveillance imaging with CT or 
MRI every 3-6 mo for 2 years, then every 6 mo for 
3-5 years. The NCCN guidelines do not recommend 
PET/CT for assessing treatment response, because 
of false-negative (necrotic lesions) and false-positive 
(inflammation and surgery) results may occur. 
CONCLUSION
Several imaging techniques are available in management 
of CRLMs. 
US plays a marginal role due to the operator-
dependence, the lack of panoramic view and the low 
sensitivity for lesions < 10 mm. US may select patients 
with diffuse secondary liver involvement who do not 
benefit of further hepatic imaging. 
Actually, ce-MDCT is the preferred imaging modality 
for initial global staging, allowing also an optimal pre-
treatment planning for curative CRLMs resection. 
MRI provides additional information respect to ce-
MDCT when suspicious or non-TSCT indeterminate 
hepatic lesions are present on ce-MDCT, in presence 
of hepatic steatosis or in the post-chemotherapy liver 
evaluation. 
18F-FDG-PET/CT may be proposed to detect occult 
extra-hepatic disease prior of CRLMs resection to avoid 
inappropriate surgical treatment. 
18F-PET-MRI may represent the future elective 
diagnostic tool because it combines the high accuracy 
for CRLMs detection of MRI with the high performance 
of extra-hepatic metastases evaluation of PET. 
Non-conventional parametric imaging may play a 
future role for detecting occult CRLMs and predicting 
which patients are at risk to develop metachronous 
liver disease, but these techniques have to be further 
investigated.
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